- Citations, last 5 years
- 113
- Works, last 5 years
- 9
- h-index
- 24
- Scientists listed
- 0
- Grants since 2016
- 21
Grants received
2025–2028 · research · R44
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
Aaron D Schuler · Syntrix Biosystems (United States) · funded by National Institutes of Health
2024–2025 · research · R44
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
Aaron D Schuler · Syntrix Biosystems (United States) · funded by National Institutes of Health
2023–2027 · research · R44
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Aaron D Schuler · Syntrix Biosystems (United States) · funded by National Institutes of Health
2023–2027 · research · R44
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Aaron D Schuler · Syntrix Biosystems (United States) · funded by National Institutes of Health
2023–2027 · research · R44
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Aaron D Schuler · Syntrix Biosystems (United States) · funded by National Institutes of Health
2019–2022 · research · R44
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2019–2020 · research · R44
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine
Miao-Kun Sun · Syntrix Biosystems (United States) · funded by National Institutes of Health
2019–2022 · research · R44
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine
Miao-Kun Sun · Syntrix Biosystems (United States) · funded by National Institutes of Health
2018–2023 · research · R44
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2018–2019 · research · R44
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2018–2021 · research · R44
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2018–2020 · research · R41
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML
Brendan Andrew Frett · Syntrix Biosystems (United States) · funded by National Institutes of Health
2017–2022 · research · R44
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2017–2018 · research · R44
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2017–2023 · research · R44
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2017–2021 · research · R44
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2015–2020 · research · R44
Phase II clinical evaluation of Omnitram in neuropathic pain
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2014–2021 · cooperative agreement · U44
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
2010–2020 · research · R44
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine
Stuart J Kahn · Syntrix Biosystems (United States) · funded by National Institutes of Health
